A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Other Phenotypes Premature death, attributed to hindbrain tauopathy, generally occurs between eight and 12 months (Dutschmann et al., 2010). Premature death is preceded by weight loss, hyperkyphosis, ...

Leucine-rich repeat kinase 2 encodes a large, complex protein containing a kinase, a GTPase, and multiple protein-protein interaction domains. The interplay of its enzymatic kinase and signaling ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

N-Terminal Strategy: All Duds So Far Initially, tau’s N-terminus was the favored target, because it produces the highest-affinity antibodies. However, antibodies that bind this region have had no ...

However, diagnostic tests do not need FDA approval to be marketed to the public. They can clear a lower bar by becoming CLIA-approved, meaning the assay has good test-retest reproducibility. Quest's ...

Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, Portugal. TauRx CEO ...

The 15th International Conference on Alzheimer’s and Parkinson’s Diseases, held virtually March 9–14, featured updates on all these programs. Mark Mintun of Eli Lilly presented donanemab ’s Phase 2 ...

Sasner sat down with Alzforum to go over what models are available now, which ones are coming, and how they could be used. The new mouse lines are the product of two different initiatives: NIA’s Model ...

There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed ...